W A Keitel1, G E Potter2, D Diemert3, J Bethony3, H M El Sahly4, J K Kennedy2, S M Patel4, J L Plieskatt3, W Jones5, G Deye5, M E Bottazzi6, P J Hotez6, R L Atmar4. 1. Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, TX, United States. Electronic address: wkeitel@bcm.edu. 2. The Emmes Corporation, United States. 3. Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Washington, DC, United States. 4. Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, TX, United States. 5. Division of Microbiology and Infectious Diseases (DMID), National Institutes of Allergy and Infectious. Diseases (NIAID), National Institutes of Health (NIH), United States. 6. Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, TX, United States; Texas Children's Hospital Center for Vaccine Development, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
Abstract
BACKGROUND: Schistosomiasis caused by Schistosoma mansoni (Sm) is a chronic, debilitating and potentially deadly neglected tropical disease. The licensure of a vaccine to prevent schistosomiasis would represent a major breakthrough in public health. METHODS: The safety and immunogenicity of a candidate Sm vaccine were assessed in this phase I, double-blind, dose-escalation trial. Seventy-two healthy Sm-naïve 18-50 year olds were randomized to receive 3 doses ∼ 8 weeks apart of saline placebo, or 10 µg, 30 µg, or 100 µg of recombinant Sm-Tetraspanin-2 vaccine formulated on aluminum hydroxide adjuvant (Sm-TSP-2/Al) with or without 5 µg of glucopyranosyl lipid A aqueous formulation (GLA-AF). Clinical and serologic responses were assessed for 1 year after dose 3. RESULTS: Vaccines were safe and well-tolerated. The most common reactions were injection site tenderness and pain, and headache and fatigue. Tenderness and pain were more frequent in groups receiving vaccine with GLA-AF than placebo (p = 0.0036 and p = 0.0014, respectively). Injection site reactions among those given Sm-TSP-2/Al with GLA-AF lasted 1.22 and 1.33 days longer than those receiving Sm-TSP-2/Al without GLA-AF or placebo (p < 0.001 for both). Dose- and adjuvant-related increases in serum IgG against Sm-TSP-2 were observed. Peak IgG levels occurred 14 days after dose 3. Seroresponse frequencies were low among recipients of Sm-TSP-2/Al without GLA-AF, but higher among subjects receiving 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF. More seroresponses were observed among those given 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF compared to placebo (p = 0.023 and p < 0.001, respectively). Seroresponse frequencies were 0%, 30%, 50%, and 89%, respectively, among those given placebo, or 10 µg, 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF, suggesting a dose-response relationship for Sm-TSP-2/Al with GLA-AF (p = 0.0001). CONCLUSIONS:Sm-TSP-2/Al with or without GLA-AF was safe and well tolerated in a Sm-naïve population. A vaccine like the one under development may represent our best hope to eliminating this neglected tropical disease.
RCT Entities:
BACKGROUND:Schistosomiasis caused by Schistosoma mansoni (Sm) is a chronic, debilitating and potentially deadly neglected tropical disease. The licensure of a vaccine to prevent schistosomiasis would represent a major breakthrough in public health. METHODS: The safety and immunogenicity of a candidate Sm vaccine were assessed in this phase I, double-blind, dose-escalation trial. Seventy-two healthy Sm-naïve 18-50 year olds were randomized to receive 3 doses ∼ 8 weeks apart of saline placebo, or 10 µg, 30 µg, or 100 µg of recombinant Sm-Tetraspanin-2 vaccine formulated on aluminum hydroxide adjuvant (Sm-TSP-2/Al) with or without 5 µg of glucopyranosyl lipid A aqueous formulation (GLA-AF). Clinical and serologic responses were assessed for 1 year after dose 3. RESULTS: Vaccines were safe and well-tolerated. The most common reactions were injection site tenderness and pain, and headache and fatigue. Tenderness and pain were more frequent in groups receiving vaccine with GLA-AF than placebo (p = 0.0036 and p = 0.0014, respectively). Injection site reactions among those given Sm-TSP-2/Al with GLA-AF lasted 1.22 and 1.33 days longer than those receiving Sm-TSP-2/Al without GLA-AF or placebo (p < 0.001 for both). Dose- and adjuvant-related increases in serum IgG against Sm-TSP-2 were observed. Peak IgG levels occurred 14 days after dose 3. Seroresponse frequencies were low among recipients of Sm-TSP-2/Al without GLA-AF, but higher among subjects receiving 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF. More seroresponses were observed among those given 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF compared to placebo (p = 0.023 and p < 0.001, respectively). Seroresponse frequencies were 0%, 30%, 50%, and 89%, respectively, among those given placebo, or 10 µg, 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF, suggesting a dose-response relationship for Sm-TSP-2/Al with GLA-AF (p = 0.0001). CONCLUSIONS:Sm-TSP-2/Al with or without GLA-AF was safe and well tolerated in a Sm-naïve population. A vaccine like the one under development may represent our best hope to eliminating this neglected tropical disease.
Authors: Mai H Tran; Mark S Pearson; Jeffrey M Bethony; Danielle J Smyth; Malcolm K Jones; Mary Duke; Tegan A Don; Donald P McManus; Rodrigo Correa-Oliveira; Alex Loukas Journal: Nat Med Date: 2006-06-18 Impact factor: 53.440
Authors: Peter J Hotez; Jeffrey M Bethony; Sergio Costa Oliveira; Paul J Brindley; Alex Loukas Journal: Expert Rev Vaccines Date: 2008-08 Impact factor: 5.217
Authors: Mai H Tran; Tori C Freitas; Leanne Cooper; Soraya Gaze; Michelle L Gatton; Malcolm K Jones; Erica Lovas; Edward J Pearce; Alex Loukas Journal: PLoS Pathog Date: 2010-04-15 Impact factor: 6.823
Authors: A E Butterworth; D W Dunne; A J Fulford; K J Thorne; K Gachuhi; J H Ouma; R F Sturrock Journal: Immunol Invest Date: 1992-08 Impact factor: 3.657
Authors: Donald P McManus; Robert Bergquist; Pengfei Cai; Shiwanthi Ranasinghe; Biniam Mathewos Tebeje; Hong You Journal: Semin Immunopathol Date: 2020-02-19 Impact factor: 9.623
Authors: Charles H King; Nara Yoon; Xiaoxia Wang; Nathan C Lo; Ramzi Alsallaq; Martial Ndeffo-Mbah; Emily Li; David Gurarie Journal: Am J Trop Med Hyg Date: 2020-07 Impact factor: 2.345
Authors: Gebeyaw G Mekonnen; Bemnet A Tedla; Darren Pickering; Luke Becker; Lei Wang; Bin Zhan; Maria Elena Bottazzi; Alex Loukas; Javier Sotillo; Mark S Pearson Journal: Vaccines (Basel) Date: 2020-07-24
Authors: Emmanuella Driciru; Jan Pieter R Koopman; Stephen Cose; Afzal A Siddiqui; Maria Yazdanbakhsh; Alison M Elliott; Meta Roestenberg Journal: Front Immunol Date: 2021-03-04 Impact factor: 7.561
Authors: Gebeyaw G Mekonnen; Bemnet A Tedla; Mark S Pearson; Luke Becker; Matt Field; Abena S Amoah; Govert van Dam; Paul L A M Corstjens; Takafira Mduluza; Francisca Mutapi; Alex Loukas; Javier Sotillo Journal: PLoS Negl Trop Dis Date: 2022-01-24